Scientists have discovered that a potential new drug can reverse severe fatty liver disease in animal models by restoring gut ...
ANAVEX®2-73 (blarcamesine) has been evaluated in the Fmr1 knockout mouse model of Fragile X syndrome in three peer-reviewed publications, Scientific Reportsi, the American Journal of Medical ...
LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting ...
Collaboration combines INmune Bio’s clinical research with QCi’s Dirac-3S quantum optimization machine to identify potential ...
We believe this resubmission reflects an efficient path to potential approval and, if approved, a potentially faster path to bringing OLC to patients who need additional treatment options.” — Shalabh ...
Polyrizon files a U.S. divisional patent application for its mucoadhesive technology in nasal drug delivery applications.
– NDA Supported by the Phase 3 PROSERA Study, Phase 2 TORREY Study and Additional Supportive Analyses – ...
On October 14, 2026, 14 items containing 11 new drug ingredients, which were approved by the Central Social Insurance Medical ...
Stockhead on MSN
ASX healthcare stocks advance new approaches to prostate cancer
ASX-listed healthcare companies are advancing new approaches to prostate cancer, spanning imaging, targeted therapies and ...
Judge Lewis J. Liman dismissed with prejudice an antitrust class-action lawsuit regarding the heart failure drug Entresto. The suit alleged ...
The European Medicines Agency (EMA) has recommended the approval of a new drug to treat advanced pancreatic cancer. The drug, ...
Collaboration combines INmune Bio's clinical research with QCi's Dirac-3S quantum optimization machine to identify potential new treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results